Platelets Surface Engineering Service

Benefiting from our proprietary cell surface engineering technology, Creative Biolabs is committed to providing the best-quality platelet surface engineering services for our global customers. We will help you achieve your project goals quickly and cost-effectively through efficient management and proactive communication.

Cell-based therapeutics are very promising modalities to address many unmet medical needs. With the evolving research and emerging innovative technologies, various cell types such as platelets have been engineering as novel therapeutics for multiple diseases and conditions. To enhance the function of these cells or cell-based therapeutics, non-genetic engineering strategies have emerged as powerful and compatible tools.

Platelets Surface Engineering Service

Platelets are tiny blood cells and critical players in hemostasis and thrombosis to target vascular injury sites to impede thrombogenesis and maintain blood circulation integrity. Cell-based systems have recently emerged as biological drug carriers; examples include erythrocytes, bacterial ghosts, and genetically engineered stem cells. Among them, the engineered platelet and platelet membrane are often used to coat nanoparticles containing the drugs to achieve enhanced treatment efficacy.

Creative Biolabs has years of experience in cell surface conjugation, providing high-quality cell surface engineering services for our global customers. We could use various technologies, such as cell-covalent conjugation and cell-noncovalent physical bioconjugation, to meet each rigorous requirement and offer high-quality platelet-based conjugate to our customers. Multiple types of platelet-based conjugates could be provided at Creative Biolabs, including but not limited to:

• Platelet-antibody conjugate
• Platelet-drug conjugate
• Platelet-fluorescent protein conjugate
• Platelet-nucleic acids conjugate (CNAC)
• Platelet-fucose conjugate (CFC)
• Platelet-peptide conjugate (CPC)
• Platelet-adjuvant-loaded nanoparticles (CALNP)

Applications of Platelets Surface Engineering

• Case 1

Researchers report the development of platelet membrane (PM)-coated core-shell nanovehicle (designated PM-NV) for targeting and sequential and site-specific delivery of the small molecular drug. First, the platelet membrane is isolated and conjugated with TRAIL via the bifunctional group sulfo-SMCC. The TRAIL-coupled platelet membrane is used to coat PLGA containing DOX to generate a dual payloads-loaded platelet membrane coated nanovesicle (TRAIL-Dox-PM-NV). By taking advantage of the specific affinity between platelets and cancer cells, this TRAIL-Dox-PM-NV can efficiently deliver TRAIL toward the cancer cell membrane to activate the extrinsic apoptosis signaling pathway leading to enhanced antitumor efficacy.

Fig.1 TRAIL-Dox-PM-NV. (Hu, 2015)

• Case 2

One research group has described a platelet membrane-coated nanoparticulate platform (designated PM-NP) for the targeted delivery of bortezomib at the myeloma site. In this research, the platelet membrane is wrapped on the surface of a polymeric nanoparticle to construct a core-shell structured nanocarrier. Next, fibrinolytic enzyme tPA is decorated on the platelet membrane via biotin-streptavidin affinity that was further decorated by targeting ligand alendronate through the sulfo-SMCC linker. Taken together, this platelet membrane-coated nanoparticle with sequential targeting actions toward the bone microenvironment and myeloma cells can enhance the drug availability at the bone marrow for promoting treatment efficacy.

Fig.2 PM-NP. (Hu, 2016)

• Case 3

In addition to engineered platelet membrane-coated nanovesicles, directly engineering whole platelets as delivery carriers have also endeavored in some researches. In one work, inspired by the intrinsic properties of platelets, researchers conjugate anti-PDL1 antibodies to the surface of platelets via a bifunctional maleimide linker. With the help of platelets, anti-PDL1 antibodies can be targeted to the cancer cells after surgery while reducing off-target effects. The result shows that platelets have promise as a means of targeted, controlled delivery of anti-PDL1 antibodies to prevent cancer recurrence post-surgery.

Fig.3 Platelet conjugated with anti-PDL1 antibodies. (Wang, 2017)

With Creative Biolabs, you will gain an experienced partner who is knowledgeable in developing cell surface conjugates. Based on your project needs, we can choose from a wide variety of available conjugation strategies to develop the most suitable platelet surface engineering for you. Please contact us for more detailed information to know how we can help.

References

1. Hu, Q.; et al. Anticancer platelet-mimicking nanovehicles. Advanced Materials. 2015, 27(44), pp.7043-7050.
2. Hu, Q.; et al. Engineered nanoplatelets for enhanced treatment of multiple myeloma and thrombus. Advanced Materials. 2016, 28(43), pp.9573-9580.
3. Wang, C.; et al. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. Nature Biomedical Engineering. 2017, 1(2), pp.1-10.